Last reviewed · How we verify
NCT04764344
Haloperidol for the Treatment of Nausea and Vomiting in the ED
Phase 4 trial testing Haloperidol in Vomiting in 60 participants. Completed in 22 May 2023.
22 May 2023
Quick facts
| Lead sponsor | Western Michigan University School of Medicine |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 April 2021 |
| Primary completion | 22 May 2023 |
| Estimated completion | 22 May 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Haloperidol (haloperidol) — full drug profile →
- Ondansetron (ondansetron) — full drug profile →
Conditions studied
- Vomiting — all drugs for Vomiting →
- Nausea — all drugs for Nausea →
- Abdominal Pain — all drugs for Abdominal Pain →
- Cannabis Use — all drugs for Cannabis Use →
Sponsor
Western Michigan University School of Medicine
Who can join
Adults 18 to 55, any sex, with Vomiting or Nausea. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300 patients age 18-55 presenting to the emergency department with chief complaint of nausea or vomiting will be enrolled from February 2021 - February 2022. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04764344
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Haloperidol
Trials testing the same drug.
- NCT06993194 — Comparison of Haloperidol and Dexmedetomidine for Delirium and Agitation in ICU Patients With Traumatic Brain Injury · NA · not yet recruiting
- NCT07087925 — Comparison of Haloperidol and Ondansetron in Reducing Postoperative Nausea and Vomiting in RA-SAB Patients · NA · completed
- NCT06395428 — Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department · Phase 4 · recruiting
- NCT06370442 — Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult · Phase 3 · not yet recruiting
- NCT06428084 — Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing PONV · Phase 2 · completed
Other recruiting trials for Vomiting
Currently open trials in the same condition.
- NCT07208305 — Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting · Phase 3 · recruiting
- NCT06954935 — Periorbital Massage for Nausea and Vomiting After Laparoscopic Surgery · NA · recruiting
- NCT06777758 — Comparison of Remimazolam and Propofol in Endoscopic Examinations and Treatments · Phase 4 · recruiting
- NCT06704698 — Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery · NA · recruiting
- NCT06582576 — Mechanisms of Action for the Enterra Medical Gastric Electrical Stimulator · recruiting
Other Western Michigan University School of Medicine trials
Trials by the same sponsor.
- NCT06395428 — Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department · Phase 4 · recruiting
- NCT07109128 — The T1D Talks Pilot Study · NA · enrolling by invitation
- NCT07504211 — Augmenting the On-Scene Medic (ATOM): A Randomized, Controlled, Multicenter Study to Assess the Effectiveness of Augment · NA · active not recruiting
- NCT02726035 — Evaluation of Naltrexone as a Treatment for Self-injurious Behavior · Phase 4 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04764344 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Western Michigan University School of Medicine
- Last refreshed: 1 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04764344.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing